Investors & MediaVectivBio AG is a global, clinical-stage biotechnology company developing innovative treatments for severe rare conditions with significant unmet medical need. We are committed to pursuing severe rare diseases with well-defined biology that can be targeted with therapies that have the potential to meaningfully transform and improve the lives of patients.
Recent News and Upcoming Events
Jul 12, 2021
VectivBio Nominates Paul R. Carter and Murray W. Stewart for Election to its Board of Directors
- Industry veterans bring decades of clinical, regulatory and commercial management expertise to VectivBio - - Nominees will stand for election at an Extraordinary General Meeting of shareholders on September 2, 2021 - BASEL, Switzerland, July 12, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG